» Articles » PMID: 30913263

Non-invasive Assessment of NAFLD As Systemic Disease-A Machine Learning Perspective

Overview
Journal PLoS One
Date 2019 Mar 27
PMID 30913263
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Current non-invasive scores for the assessment of severity of non-alcoholic fatty liver disease (NAFLD) and identification of patients with non-alcoholic steatohepatitis (NASH) have insufficient performance to be included in clinical routine. In the current study, we developed a novel machine learning approach to overcome the caveats of existing approaches.

Methods: Non-invasive parameters were selected by an ensemble feature selection (EFS) from a retrospectively collected training cohort of 164 obese individuals (age: 43.5±10.3y; BMI: 54.1±10.1kg/m2) to develop a model able to predict the histological assessed NAFLD activity score (NAS). The model was evaluated in an independent validation cohort (122 patients, age: 45.2±11.75y, BMI: 50.8±8.61kg/m2).

Results: EFS identified age, γGT, HbA1c, adiponectin, and M30 as being highly associated with NAFLD. The model reached a Spearman correlation coefficient with the NAS of 0.46 in the training cohort and was able to differentiate between NAFL (NAS≤4) and NASH (NAS>4) with an AUC of 0.73. In the independent validation cohort, an AUC of 0.7 was achieved for this separation. We further analyzed the potential of the new model for disease monitoring in an obese cohort of 38 patients under lifestyle intervention for one year. While all patients lost weight under intervention, increasing scores were observed in 15 patients. Increasing scores were associated with significantly lower absolute weight loss, lower reduction of waist circumference and basal metabolic rate.

Conclusions: A newly developed model (http://CHek.heiderlab.de) can predict presence or absence of NASH with reasonable performance. The new score could be used to detect NASH and monitor disease progression or therapy response to weight loss interventions.

Citing Articles

Identification of Fast Progressors Among Patients With Nonalcoholic Steatohepatitis Using Machine Learning.

Schattenberg J, Balp M, Reinhart B, Porwal S, Tietz A, Pedrosa M Gastro Hep Adv. 2024; 3(1):101-108.

PMID: 39132186 PMC: 11307632. DOI: 10.1016/j.gastha.2023.09.004.


Liver Diseases: Science, Fiction and the Foreseeable Future.

Gieseler R, Baars T, Ozcurumez M, Canbay A J Pers Med. 2024; 14(5).

PMID: 38793074 PMC: 11122384. DOI: 10.3390/jpm14050492.


Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment.

Savari F, Mard S Heliyon. 2024; 10(7):e28468.

PMID: 38689985 PMC: 11059522. DOI: 10.1016/j.heliyon.2024.e28468.


Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information.

McTeer M, Applegate D, Mesenbrink P, Ratziu V, Schattenberg J, Bugianesi E PLoS One. 2024; 19(2):e0299487.

PMID: 38421999 PMC: 10903803. DOI: 10.1371/journal.pone.0299487.


Machine learning approaches for early detection of non-alcoholic steatohepatitis based on clinical and blood parameters.

Naderi Yaghouti A, Zamanian H, Shalbaf A Sci Rep. 2024; 14(1):2442.

PMID: 38287043 PMC: 10824722. DOI: 10.1038/s41598-024-51741-0.


References
1.
Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J . Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999; 257(1):79-83. DOI: 10.1006/bbrc.1999.0255. View

2.
Harrison S, Oliver D, ARNOLD H, Gogia S, Neuschwander-Tetri B . Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008; 57(10):1441-7. DOI: 10.1136/gut.2007.146019. View

3.
Angulo P, Kleiner D, Dam-Larsen S, Adams L, Bjornsson E, Charatcharoenwitthaya P . Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015; 149(2):389-97.e10. PMC: 4516664. DOI: 10.1053/j.gastro.2015.04.043. View

4.
Byrne C, Targher G . NAFLD: a multisystem disease. J Hepatol. 2015; 62(1 Suppl):S47-64. DOI: 10.1016/j.jhep.2014.12.012. View

5.
Kalsch J, Bechmann L, Heider D, Best J, Manka P, Kalsch H . Normal liver enzymes are correlated with severity of metabolic syndrome in a large population based cohort. Sci Rep. 2015; 5:13058. PMC: 4535035. DOI: 10.1038/srep13058. View